



PRESENTS:



DATE WITH A CURE

A FREE ALZHEIMER'S RESEARCH FORUM

Welcome!



Eugenia Welch
President & CEO



Thank you!



Keck School of
Medicine of **USC**


**Alzheimer's Therapeutic
Research Institute**





~~84K~~ \approx 100,000

people in San Diego County
living with dementia



Join us!



MOTORCYCLE RIDE TO BENEFIT
Alzheimer's | SAN DIEGO

July 10, 2021



BALBOA PARK • WALK4ALZ

Alzheimer's | SAN DIEGO

October 16, 2021



Darlene Marcos Shiley

COLLABORATION4CURE
END ALZHEIMER'S



PRESENTS:





DATE WITH A CURE

A FREE ALZHEIMER'S RESEARCH FORUM

About the program

- All attendees have been muted
- This program is being recorded
- Program materials will be emailed
- Use “Q&A” to submit questions
- A live “closed caption” transcript of this program is available





*Alzheimer's San Diego's **Volunteer Tech Team** is here to help! Call our office (858-492-4400) or send a message in the webinar "chat" if you need technical assistance during the program.*



Amy Abrams, MSW/MPH
Moderator

Director of Education
Alzheimer's San Diego




Dr. Paul S. Aisen

Director
USC Alzheimer's Therapeutic
Research Institute



Dr. Jim Brewer

Director
UCSD's Shiley-Marcos
Alzheimer's Disease
Research Center



Dr. Jerold Chun

Senior Vice President,
Neuroscience Drug Discovery
Sanford Burnham Prebys
Medical Discovery Institute



Dr. Brent Mausbach

Clinical Psychologist
UC San Diego Health



Dr. Michael Plopper

Medical Director
Sharp Clinical Research
Center



Dr. Robert Rissman

Associate Professor of
Neurosciences
UCSD Center for
Neurodegeneration &
Experimental
Neuropathology



Dr. Sherry Soefje

COO and Medical Director
Excell Research



Dementia's impact in San Diego County


≈**100,000** residents of San Diego
County 55+ are living with dementia.

3rd leading cause of death


By 2030, there will be over **115,000**
San Diegans living with dementia,
requiring nearly 300,000 caregivers
to provide over 333 million hours of
unpaid care annually.

Source: County of San Diego Health and Human Services Agency

Dementia is not a specific disease



Risk factors for dementia




*Ethnic disparities
in the U.S.*

*No known
environmental
risk factors or
causes*

Staying healthy

- Diet and nutrition
- Exercise and movement
- Cognitive activity
- Social connection
- Sleep and relaxation

*What's good for your heart
is good for your brain.*



The needs of people living with dementia, family caregivers, and the community at large

- Information
- Emotional support
- Respite
- Social connection
- Safety resources





- Information and resources
- Printable tip sheets
- Video library

alzsd.org

- Information and referral
- Care consultation
- Emotional support

(858) 492-4400

info@alzsd.org



A groundbreaking local initiative that combines San Diego's resources in order to accelerate research and drug discovery projects to find a cure.



When you join a clinical trial, you contribute to critical research that could change the course of Alzheimer's disease treatment and cure.



High Throughput Screening Studies for Novel N-Terminal CRFR1 Antagonists for AD

Robert Rissman, PhD

Associate Professor of Neurosciences

Director, ADCS Biomarker Core

Director, ADRC Neuropath & Biomarker Cores

University of California, San Diego

Director, ATRI Biomarker Unit

Director, National Clinical Trial Repository for AD


University of Southern California

Principal Investigator and Research Biologist

VA San Diego Healthcare System



Corticotropin-Releasing Factor Receptor 1 (CRFR1) as a target for AD

CRF Family of Ligands and Receptors



CRF System Involvement in AD?

- CRF-immunoreactivity is reduced early in AD
- Occurs in areas vulnerable to AD pathology
- Abnormal CRF neurites surround A β plaques
- CRF binding upregulated in vulnerable cortical areas



Stress and CRF Signaling in Alzheimer's Disease: Extension to Mouse Model of AD

- CRF antagonist treatment can retard/limit development of plaque pathology in mouse AD model independent of stress experience
 - also lessen β -amyloid production, cognitive impairment
 - similar, though more subtle effects seen in older animals
- CRFR1 antagonists target both pathological hallmarks of AD
- CRFR1 is a candidate target for intervention in AD
 - Small molecule CRFR1 antagonists have been tested in human trials
 - Route of administration may be an important determinant of efficacy

C4C Update

Reverse transcriptase inhibitors and sphingosine 1-phosphate (S1P) receptor 2 (S1P₂) antagonists

Jerold Chun, M.D., Ph.D.


SBP

Medical
Discovery
Institute

SANFORD BURNHAM PREBYS


La Jolla, CA USA

jchun@SBPdiscovery.org



Reverse transcriptase inhibitors to reduce AD genomic complementary DNAs: gencDNAs



AD gencDNAs are produced by reverse transcriptases (RTs): **this C4C goal is to find inhibitors of human brain RTs**




gencDNAs produced by **somatic gene recombination**
involve **myriad** normal or pathogenic gene forms in AD

S1P₂ antagonists

This C4C goal is to reduce neurodegeneration in AD by decreasing glutamate neurotoxicity by inhibiting S1P₂



The EphA4 Receptor as a Novel Target against Alzheimer's



Ask the experts




Amy Abrams, MSW/MPH



Dr. Paul S. Aisen



Dr. Jim Brewer



Dr. Jerold Chun



Dr. Brent Mausbach



Dr. Michael Plopper



Dr. Robert Rissman



Dr. Sherry Soefje



DATE WITH
A CURE



THANK YOU FOR JOINING US!



DATE WITH
A CURE

A FREE ALZHEIMER'S RESEARCH FORUM